Epiminder (ASX:EPI) reached 25 enrolled patients in its DETECT (Diagnosing Epilepsy To EffeCT change) clinical study in the US, according to a Monday filing with the Australian bourse.

The study is evaluating the Minder system, an implantable device for continuous monitoring of brain activity, as a tool to improve clinical decision-making for patients with epilepsy after an inconclusive prolonged electroencephalographic monitoring assessment, the filing said.

The company is progressing toward its next enrolment target of 50 patients, expected in the third quarter of the year, and is on track to meet its stated target of 210 patients by the end of the first half of 2027, per the filing.